- Trends in regenerative medicine
- Partnering agreement structure
- Partnering contract documents
- Top deals by value
- Most active dealmakers
- Average deal terms for regenerative medicine and stem cells
The report provides a detailed understanding and analysis of how and why companies enter Regenerative Medicine partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
This report provides details of the latest Regenerative Medicine agreements announced in the life sciences since 2015.
The report takes the reader through a comprehensive review Regenerative Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Regenerative Medicine partnering deals.
The report presents financial deal term values for Regenerative Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Regenerative Medicine partnering field; both the leading deal values and most active Regenerative Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 1600 online deal records of actual Regenerative Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of Regenerative Medicine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Regenerative Medicine dealmaking since 2015, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Regenerative Medicine deals since 2015. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Regenerative Medicine dealmaking with a brief summary followed by a comprehensive listing of Regenerative Medicine deals announced by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of Regenerative Medicine partnering deals signed and announced since Jan 2015, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Regenerative Medicine partnering deals signed and announced since Jan 2015. The chapter is organized by specific Regenerative Medicine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by Regenerative Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Regenerative Medicine partnering and dealmaking since 2015.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Regenerative Medicine technologies and products.
Global Regenerative Medicine Partnering Terms and Agreements 2015-2022 provides the reader with the following key benefits:
- In-depth understanding of Regenerative Medicine deal trends since 2015
- Access to headline, upfront, milestone and royalty data
- Detailed access to actual Regenerative Medicine contracts entered into by leading biopharma companies
- Identify most active Regenerative Medicine dealmakers since 2015
- Insight into terms included in a Regenerative Medicine partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Global Regenerative Medicine Partnering Terms and Agreements 2015-2022 is intended to provide the reader with an in-depth understanding and access to Regenerative Medicine trends and structure of deals entered into by leading companies worldwide.
Regenerative Medicine Partnering Terms and Agreements includes:
- Trends in Regenerative Medicine dealmaking in the biopharma industry since 2015
- Access to headline, upfront, milestone and royalty data
- Access to Regenerative Medicine contract documents
- Leading Regenerative Medicine deals by value since 2015
- Most active Regenerative Medicine dealmakers since 2015
In Global Regenerative Medicine Partnering Terms and Agreements 2015-2022, the available deals are listed by:
- - Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Regenerative Medicine Partnering terms and Agreements 2015-2022 report provides comprehensive access to available deals and contract documents for over 1600 Regenerative Medicine deals.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
2.2. Regenerative Medicine partnering over the years
2.3. Most active Regenerative Medicine dealmakers
2.4. Regenerative Medicine partnering by deal type
2.5. Regenerative Medicine partnering by therapy area
2.6. Deal terms for Regenerative Medicine partnering
2.6.1 Regenerative Medicine partnering headline values
2.6.2 Regenerative Medicine deal upfront payments
2.6.3 Regenerative Medicine deal milestone payments
2.6.4 Regenerative Medicine royalty rates
3.2. Top Regenerative Medicine deals by value
4.2. Most active Regenerative Medicine dealmakers
4.3. Most active Regenerative Medicine partnering company profiles
5.2. Regenerative Medicine contracts dealmaking directory
Appendix 2 - Regenerative Medicine deals by stage of development
Appendix 3 - Regenerative Medicine deals by deal type
Appendix 4 - Regenerative Medicine deals by therapy area
Appendix 5 - Deal type definitions
Appendix 6 - Further Reading
Figure 2: Active Regenerative Medicine dealmaking activity
Figure 3: Regenerative Medicine partnering by deal type since 2015
Figure 4: Regenerative Medicine partnering by disease type since 2015
Figure 5: Regenerative Medicine deals with a headline value
Figure 6: Regenerative Medicine deals with an upfront value
Figure 7: Regenerative Medicine deals with a milestone value
Figure 8: Regenerative Medicine deals with a royalty rate value
Figure 9: Top Regenerative Medicine deals by value since 2015
Figure 10: Most active Regenerative Medicine dealmakers sinc 2015
A selection of companies mentioned in this report includes:
- 2seventy bio
- 3D Medicines
- 3D Systems
- 4basebio Discovery
- 4D Molecular Therapeutics
- 180 Life Sciences
- A*STAR Agency for Science
- Technology and Research
- A*STAR Genome Institute of Singapore
- A*STAR’ Institute of Molecular and Cell Biology
- A2 Biotherapeutics
- Abby Grace Foundation
- Abeona Therapeutics
- Abingworth Management
- Abintus Bio
- Abound Bio
- Abu Dhabi Stem Cells Center
- Accelerated Biosciences
- Accelerator for Technological Research in Genomic Therapies
- ACEA Biosciences
- Aceso Life Science
- Achilles Therapeutics
- Actinium Pharmaceuticals
- Adaptive Biotechnologies
- Addex Therapeutics
- Adicet Bio
- Adva Biotechnology
- Advanced Biological Innovation and Manufacturing
- Advanced BioScience Laboratories
- Advanced Biotherapeutics Consulting
- Advanced Regenerative Manufacturing Institute
- Aelan Cell Technologies
- Aevitas Therapeutics
- Affinia Therapeutics
- AffyXell Therapeutics
- Agathos Biologics
- AGC Asahi Glass
- AgeX Therapeutics
- Agilis Biotherapeutics
- AiVita Biomedical
- Akadeum Life Sciences
- Akashi Therapeutics
- Akoya Biosciences
- Alcyone Lifesciences
- Alder Biopharmaceuticals
- Aleta Biotherapeutics
- Alkem Laboratories
- Allele Biotechnology and Pharmaceuticals
- Allen Institute for Brain Science
- Alliance for Cancer Gene Therapy
- Alliance for Regenerative Medicine
- Alliqua Biomedical
- Allogene Overland Biopharm
- Allogene Therapeutics
- Alloplex Biotherapeutics
- Almog Diagnostic
- Alnylam Pharmaceuticals
- Alpha Biopharma
- Alphageneron Pharmaceuticals
- Alpine Immune Sciences
- ALS Finding a Cure Foundation
- Altor BioScience
- Amarna Therapeutics
- Ambys Medicines
- American Association of Neuromuscular & Electrodiagnostic Medicine
- American CryoStem
- American Gene Technologies
- American National Multiple Sclerosis Society
- American Society of Gene and Cell Therapy
- American Society of Hematology
- American Type Culture Collection (ATCC)
- Amicus Therapeutics
- Anagenesis Biotechnologies
- Ankarys Therapeutics
- Annapurna Therapeutics
- Anthony Nolan
- Antibe Therapeutics
- Antion Biosciences
- Apeiron Biologics
- APEX Biologix
- Apollo Therapeutics
- Appia Bio
- Applied DNA Sciences
- Applied StemCell
- Aquitaine Science Transfert (SATT Aquitaine)
- Araim Pharmaceuticals
- aratinga.bio SAS Group
- Arbor Biotechnologies
- Arch Therapeutics
- Arctic Vision
- Arranta Bio
- Artisan Bio
- Artiva Biotherapeutics
- Aruvant Sciences
- Asahi Kasei
- Asana Medical
- Ascendance Biotechnology
- ASC Therapeutics
- Asklepios Biopharmaceutical
- Aspect Biosystems
- Assembly Biosciences
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Collaborative R&D
- Contract service
- Equity purchase
- Joint venture
- Royalty financing
- Spin out
- Sub license
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.